Guardant Health, Inc.

NasdaqGS:GH Stock Report

Market Cap: US$5.8b

Guardant Health Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Helmy Eltoukhy

Chief executive officer

US$11.6k

Total compensation

CEO salary percentage0.009%
CEO tenure12yrs
CEO ownership2.2%
Management average tenure3.7yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 43% Share Price Bounce

Jan 22
Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 43% Share Price Bounce

Guardant Health: Remains Risky Despite SHIELD's Early Success

Jan 21

Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching

Dec 31
Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching

Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

Nov 08
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Oct 25
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31
Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12
Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04
Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14
Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Helmy Eltoukhy's remuneration changed compared to Guardant Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$512m

Jun 30 2024n/an/a

-US$491m

Mar 31 2024n/an/a

-US$461m

Dec 31 2023US$12kUS$1

-US$479m

Sep 30 2023n/an/a

-US$432m

Jun 30 2023n/an/a

-US$508m

Mar 31 2023n/an/a

-US$665m

Dec 31 2022US$12kUS$1

-US$655m

Sep 30 2022n/an/a

-US$606m

Jun 30 2022n/an/a

-US$551m

Mar 31 2022n/an/a

-US$419m

Dec 31 2021US$14kUS$1

-US$406m

Sep 30 2021n/an/a

-US$409m

Jun 30 2021n/an/a

-US$379m

Mar 31 2021n/an/a

-US$336m

Dec 31 2020US$114mUS$210k

-US$254m

Sep 30 2020n/an/a

-US$185m

Jun 30 2020n/an/a

-US$120m

Mar 31 2020n/an/a

-US$77m

Dec 31 2019US$915kUS$500k

-US$76m

Sep 30 2019n/an/a

-US$76m

Jun 30 2019n/an/a

-US$87m

Mar 31 2019n/an/a

-US$97m

Dec 31 2018US$818kUS$480k

-US$85m

Compensation vs Market: Helmy's total compensation ($USD11.59K) is below average for companies of similar size in the US market ($USD7.82M).

Compensation vs Earnings: Helmy's compensation has been consistent with company performance over the past year.

CEO

Helmy Eltoukhy (45 yo)

12yrs

Tenure

US$11,591

Compensation

Dr. Helmy Eltoukhy, Ph D., is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC.Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health,...

Leadership Team

NamePositionTenureCompensationOwnership
Helmy Eltoukhy
Co-Founder12yrsUS$11.59k2.18%
$ 127.0m
AmirAli Talasaz
Co-CEO & Director3.4yrsUS$26.42k1.83%
$ 106.7m
Michael Bell
Chief Financial Officer4yrsUS$4.12m0.023%
$ 1.4m
Darya Chudova
Chief Technology Officerno dataUS$4.76m0.046%
$ 2.7m
Craig Eagle
Chief Medical Officer3.7yrsUS$3.49m0.021%
$ 1.2m
Christopher Freeman
Chief Commercial Officer3.6yrsUS$3.52m0.028%
$ 1.6m
Kumud Kalia
Chief Information Officer5yrsno data0.016%
$ 943.6k
Zarak Khurshid
Vice President of Investor Relationsno datano datano data
John Saia
Chief Legal Officer & Corporate Secretary4.7yrsUS$6.02m0.028%
$ 1.6m
Jennifer Higgins
Senior Vice President of Public Affairsno datano datano data
Stephen Murphy
Senior Vice President of Marketing1yrno datano data
Terilyn Monroe
Chief People Officer1yrno data0.0097%
$ 562.8k

3.7yrs

Average Tenure

51yo

Average Age

Experienced Management: GH's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Helmy Eltoukhy
Co-Founder12yrsUS$11.59k2.18%
$ 127.0m
AmirAli Talasaz
Co-CEO & Director12yrsUS$26.42k1.83%
$ 106.7m
Myrtle Potter
Independent Director3.3yrsUS$425.21k0.011%
$ 650.8k
Ian T. Clark
Lead Independent Director8yrsUS$470.21k0.0068%
$ 398.3k
Roberto Mignone
Directorless than a yearno datano data
Steve Krognes
Independent Director2.6yrsUS$425.21k0.0083%
$ 482.3k
Musa Tariq
Independent Director1.8yrsUS$725.30k0.0024%
$ 138.8k
Vijaya Gadde
Independent Director4.6yrsUS$425.21k0.014%
$ 832.8k
Meghan Joyce
Independent Director3.4yrsUS$425.21k0.0062%
$ 362.7k
Manuel Medina
Directorless than a yearno datano data

3.3yrs

Average Tenure

50.5yo

Average Age

Experienced Board: GH's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 23:34
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guardant Health, Inc. is covered by 30 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael RyskinBofA Global Research
Derik de BruinBofA Global Research
Mark MassaroBTIG